<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01963481</url>
  </required_header>
  <id_info>
    <org_study_id>13-00761</org_study_id>
    <nct_id>NCT01963481</nct_id>
  </id_info>
  <brief_title>Exemestane and Cyclophosphamide for Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Trial of Exemestane With Immunomodulatory Cyclophosphamide in ER and/or PR-positive and HER2/Neu Negative Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well exemestane and cyclophosphamide work in treating
      patients with estrogen receptor (ER) -positive, progesterone receptor (PR) -positive, and
      human epidermal growth factor receptor (HER)2-negative stage IV breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane may
      fight breast cancer by blocking the use of estrogen by the tumor cells. Low dose
      cyclophosphamide may also stimulate the white blood cells, including natural killer cells,
      for instance by decreasing the suppressor (regulatory) T-cells. Giving exemestane with
      cyclophosphamide may be an effective treatment for estrogen receptor-positive, progesterone
      receptor-positive, and HER2-negative stage IV breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">October 1, 2017</completion_date>
  <primary_completion_date type="Actual">October 1, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) Rate at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>PFS is defined as the time from first treatment day until objective disease progression or death from any cause. Assessment of disease progression based on Response Evaluation Criteria in Solid Tumor (RESIST) guideline version 1.1 is performed every 12 weeks on study. The percent of participants with PFS at 3 months will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate (RR) - Complete Response and Partial Response</measure>
    <time_frame>2 years</time_frame>
    <description>Complete response (CR) is defined as the disappearance of all target lesions, while partial response (PR) is when at least a 30% decrease in the sum of the diameters of target lesions. Evaluation of response is based on RESIST guideline version 1.1. RR is reported as percentage of participants with a CR and/or PR at 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate Score</measure>
    <time_frame>3 years</time_frame>
    <description>Clinical benefit rate is defined as the percentage of patients who have achieved objective response or stable disease for at least 24 weeks. Evaluation of response and disease progression is based on RESIST guideline version 1.1. Response and progression are assessed every 12 weeks.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Metastatic Beast Cancer</condition>
  <arm_group>
    <arm_group_label>Exemestane and cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A treatment cycle is defined as 4 weeks:
One tablet (25 mg) of exemestane and one tablet (50 mg) of cyclophosphamide given daily by mouth until disease progression or unacceptable adverse events.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <arm_group_label>Exemestane and cyclophosphamide</arm_group_label>
    <other_name>Aromasin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Exemestane and cyclophosphamide</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>CTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically confirmed breast cancer that is ER positive and/or
             PR positive, and HER2/neu negative and have disease that is metastatic (stage IV)

               -  HER2/neu negative disease determined using commercially available/approved assay
                  in local institutional or reference laboratory, according to American Society of
                  Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines (IHC
                  0-1+ or 2+ with HER2/17 ratio on FISH &lt;= 1.8).

               -  ER/PR expression performed by standard immunohistochemical assay and classified
                  as ER and/or PR-positive according to ASCO/CAP guidelines (1-100% expression)

               -  Histologic and/or cytologic confirmation of metastatic disease is encouraged
                  whenever feasible, furthermore, if feasible, the biopsy should confirm that the
                  metastatic tumor is ER and/or PR positive and HER2/neu negative. For patients in
                  whom histologic biopsy confirmation and/or assessment of ER/PR/HER2 of metastatic
                  disease is not feasible, it is required that the primary tumor be ER and/or
                  PR-positive and HER2/neu negative.

          -  Measurable disease (RECIST 1.1) or non-measurable (assessable) disease

          -  Patients must have had progressive disease during at least one line of endocrine
             therapy for metastatic disease or have recurrent disease while or within 12 months of
             receiving adjuvant endocrine therapy. Prior treatments accepted include a
             non-steroidal aromatase inhibitor, tamoxifen, fulvestrant or combinations.

          -  Patients taking bisphosphonates for bone disease are permitted to enter the trial, but
             their bone lesions are not considered to be assessable for response, although they are
             assessable for progression.

          -  Female or male subjects age &gt;= 18 years.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.

          -  Patients must have normal organ and marrow function as defined below:

               -  absolute neutrophil count &gt;= 1,200/mcL

               -  platelets &gt;= 100,000/mcL

               -  hemoglobin &gt;= 9g/dl

               -  total bilirubin &lt;= 2 X upper limit of normal (ULN) [unless due to Gilbert's
                  disease]

               -  AST(SGOT) &lt;= 2.5 X ULN

               -  ALT(SGPT) &lt;= 2.5 X ULN

               -  creatinine &lt;= 1.5 X ULN

          -  Patients must be able to swallow and tolerate oral medications.

          -  Postmenopausal status, defined as 60 years and older, being 45 years and older and
             having amenorrhea x 12 months or follicle stimulating hormone levels within
             postmenopausal range, OR having undergone a bilateral oophorectomy.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Patients may not be receiving any other investigational agents.

          -  Prior treatment for breast cancer with a steroidal aromatase inhibitor; with the
             exception of patients who were started on the combination of exemestane with
             everolimus less than 4 weeks prior to study entry and discontinued everolimus due to
             poor tolerability.

          -  Presence of life threatening metastatic visceral disease (defined as extensive hepatic
             involvement or symptomatic pulmonary lymphangitic spread) or uncontrolled brain
             metastases.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvia Adams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Perlmutter Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 11, 2013</study_first_submitted>
  <study_first_submitted_qc>October 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2013</study_first_posted>
  <results_first_submitted>April 24, 2019</results_first_submitted>
  <results_first_submitted_qc>March 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 17, 2020</results_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hormonal therapy</keyword>
  <keyword>immunotherapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 12, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT01963481/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Exemestane and Cyclophosphamide</title>
          <description>A treatment cycle is defined as 4 weeks:
One tablet (25 mg) of exemestane and one tablet (50 mg) of cyclophosphamide given daily by mouth until disease progression or unacceptable adverse events.
Exemestane
Cyclophosphamide</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Exemestane and Cyclophosphamide</title>
          <description>A treatment cycle is defined as 4 weeks:
One tablet (25 mg) of exemestane and one tablet (50 mg) of cyclophosphamide given daily by mouth until disease progression or unacceptable adverse events.
Exemestane
Cyclophosphamide</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS) Rate at 3 Months</title>
        <description>PFS is defined as the time from first treatment day until objective disease progression or death from any cause. Assessment of disease progression based on Response Evaluation Criteria in Solid Tumor (RESIST) guideline version 1.1 is performed every 12 weeks on study. The percent of participants with PFS at 3 months will be reported.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exemestane and Cyclophosphamide</title>
            <description>A treatment cycle is defined as 4 weeks:
One tablet (25 mg) of exemestane and one tablet (50 mg) of cyclophosphamide given daily by mouth until disease progression or unacceptable adverse events.
Exemestane
Cyclophosphamide</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) Rate at 3 Months</title>
          <description>PFS is defined as the time from first treatment day until objective disease progression or death from any cause. Assessment of disease progression based on Response Evaluation Criteria in Solid Tumor (RESIST) guideline version 1.1 is performed every 12 weeks on study. The percent of participants with PFS at 3 months will be reported.</description>
          <units>percent of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.1" lower_limit="33.0" upper_limit="76.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate (RR) - Complete Response and Partial Response</title>
        <description>Complete response (CR) is defined as the disappearance of all target lesions, while partial response (PR) is when at least a 30% decrease in the sum of the diameters of target lesions. Evaluation of response is based on RESIST guideline version 1.1. RR is reported as percentage of participants with a CR and/or PR at 2 years.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exemestane and Cyclophosphamide</title>
            <description>A treatment cycle is defined as 4 weeks:
One tablet (25 mg) of exemestane and one tablet (50 mg) of cyclophosphamide given daily by mouth until disease progression or unacceptable adverse events.
Exemestane
Cyclophosphamide</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate (RR) - Complete Response and Partial Response</title>
          <description>Complete response (CR) is defined as the disappearance of all target lesions, while partial response (PR) is when at least a 30% decrease in the sum of the diameters of target lesions. Evaluation of response is based on RESIST guideline version 1.1. RR is reported as percentage of participants with a CR and/or PR at 2 years.</description>
          <units>percent of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" lower_limit="10.2" upper_limit="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Benefit Rate Score</title>
        <description>Clinical benefit rate is defined as the percentage of patients who have achieved objective response or stable disease for at least 24 weeks. Evaluation of response and disease progression is based on RESIST guideline version 1.1. Response and progression are assessed every 12 weeks.</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exemestane and Cyclophosphamide</title>
            <description>A treatment cycle is defined as 4 weeks:
One tablet (25 mg) of exemestane and one tablet (50 mg) of cyclophosphamide given daily by mouth until disease progression or unacceptable adverse events.
Exemestane
Cyclophosphamide</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit Rate Score</title>
          <description>Clinical benefit rate is defined as the percentage of patients who have achieved objective response or stable disease for at least 24 weeks. Evaluation of response and disease progression is based on RESIST guideline version 1.1. Response and progression are assessed every 12 weeks.</description>
          <units>percent of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8" lower_limit="26.8" upper_limit="69.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>13.7 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Exemestane and Cyclophosphamide</title>
          <description>A treatment cycle is defined as 4 weeks:
One tablet (25 mg) of exemestane and one tablet (50 mg) of cyclophosphamide given daily by mouth until disease progression or unacceptable adverse events.
Exemestane
Cyclophosphamide</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="23" subjects_affected="10" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sylvia Adams</name_or_title>
      <organization>NYU Langone Health</organization>
      <phone>212 731 5795</phone>
      <email>Sylvia.Adams@nyulangone.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

